Angiomodulatory properties of Rhodiola spp. and other natural antioxidants

Dorota M Radomska-Leśniewska1, Piotr Skopiński2, Barbara J Bałan3

  • 1Department of Histology and Embryology, Medical University of Warsaw, Warsaw, Poland.

Insights

Antioxidants, used to combat oxidative stress, can modulate angiogenesis, impacting disease treatment. This review analyzes natural and supplemental antioxidants for their effects on blood vessel formation and therapeutic potential in angiogenesis-related diseases.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cell Biology

Background:

  • Disturbances in angiogenesis and oxidative stress are linked to diseases like cancer, diabetes, and ischemic heart disease.
  • Antioxidants neutralize oxidative stress and can influence angiogenesis, potentially affecting therapeutic outcomes.
  • The use of antioxidants is increasing for maintaining homeostasis and reducing disease risk.

Purpose of the Study:

  • To review the angiogenic properties and molecular effects of various natural and supplemental antioxidants.
  • To analyze the medical applications of these antioxidants in managing angiogenesis-related conditions.
  • To evaluate the safety and efficacy of antioxidants in patients with abnormal angiogenesis.

Main Methods:

  • Review of scientific literature on antioxidant preparations and their effects on angiogenesis.
  • Analysis of in vitro and in vivo (animal models) studies.
  • Examination of clinical applications and safety profiles.

Main Results:

  • Most reviewed antioxidants down-regulate neovascularization and can be safely used in patients with high angiogenesis.
  • Rhodiola modulates, while Echinacea, Aloe vera, and Plumbagin inhibit tumor-related angiogenesis.
  • Resveratrol and Resvega reduce ocular neovascularization, and Padma 28 exhibits angioregulatory activity, beneficial for various angiogenesis disturbances.

Conclusions:

  • Antioxidants possess significant potential in managing angiogenesis-related diseases.
  • The choice of antioxidant therapy should consider the patient's specific angiogenic status.
  • Further research into the precise molecular mechanisms and clinical efficacy is warranted.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
3.0K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.8K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
3.1K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.8K